Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAHOGANY: Margetuximab Combinations in HER2+ Gastric/GEJ Cancer
NCT04082364Phase 3Completed
- Sponsor
- MacroGenics
- Start
- Sep 2019
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of margetuximab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by MacroGenics. Started Sep 2019; status: completed.
02
Drugs
margetuximab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04082364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082364.